Business Context and Reporting Period
Company: Sana Biotechnology, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 15, 2026
Event: Item 8.01 Other Events – Equity Offering under Sales Agreement
Key Financial Metrics
This filing reports a specific capital raising event rather than periodic financial performance. The following metrics are disclosed:
- Shares Sold: 21,607,878 shares of common stock
- Net Proceeds: Approximately $69.0 million
- Sales Agent: TD Securities (USA) LLC
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these metrics.
Material Changes
The material change reported is the increase in outstanding common stock and the influx of cash proceeds from the sale of 21,607,878 shares. No comparative period data is provided in this specific filing to quantify changes in operating metrics.
Guidance, Outlook, and Risks
Management Commentary: The Company announced the completion of the sale pursuant to its amended and restated sales agreement.
Guidance and Outlook: The filing text does not provide a clear value for future guidance or outlook.
Risks and Contingencies: No specific risks or contingencies are detailed in this excerpt beyond the standard disclosure of the equity sale.
Investor Verification Checklist
- Verify the exact average price per share implied by the $69.0 million net proceeds and 21,607,878 shares sold.
- Confirm the updated total share count and potential dilution impact on existing shareholders.
- Review the amended and restated sales agreement with TD Securities (USA) LLC for commission rates and termination clauses.
- Check subsequent filings (e.g., 10-Q or 10-K) to determine how these proceeds are allocated (e.g., R&D, debt repayment, general corporate purposes).